Maplight Therapeutics, INC S-1 registration statements

MapLight Therapeutics, Inc. has filed an S-1/A amendment to register for resale up to 13,181,055 shares of common stock held by selling stockholders, following a private placement.

MapLight Therapeutics, Inc. has filed an S-1 registration statement to allow selling stockholders to resell up to 13,181,055 shares of common stock, following a private placement.

MapLight Therapeutics, a clinical-stage biopharmaceutical company, is launching its initial public offering to fund the advancement of its central nervous system disorder pipeline, despite ongoing substantial losses and a 'going concern' warning.

Clinical-stage biopharmaceutical company MapLight Therapeutics files S-1 for initial public offering to advance CNS disorder therapies, including lead candidates for schizophrenia and Alzheimer's psychosis.